CA3184128A1 - Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes - Google Patents

Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Info

Publication number
CA3184128A1
CA3184128A1 CA3184128A CA3184128A CA3184128A1 CA 3184128 A1 CA3184128 A1 CA 3184128A1 CA 3184128 A CA3184128 A CA 3184128A CA 3184128 A CA3184128 A CA 3184128A CA 3184128 A1 CA3184128 A1 CA 3184128A1
Authority
CA
Canada
Prior art keywords
methylation
subject
infection
covid
classifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3184128A
Other languages
English (en)
French (fr)
Inventor
Kathleen Barnes
Ivana YANG
Christopher GIGNOUX
Rasika MATHIAS
Paul Norman
Alem TAYE
Rishi Porecha
Bret BARNES
Brett Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Denver
Illumina Software Inc
Original Assignee
University of Colorado Denver
Illumina Software Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Denver, Illumina Software Inc filed Critical University of Colorado Denver
Publication of CA3184128A1 publication Critical patent/CA3184128A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA3184128A 2020-06-23 2021-06-23 Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes Pending CA3184128A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042669P 2020-06-23 2020-06-23
US63/042,669 2020-06-23
PCT/US2021/038763 WO2021262894A1 (en) 2020-06-23 2021-06-23 Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Publications (1)

Publication Number Publication Date
CA3184128A1 true CA3184128A1 (en) 2021-12-30

Family

ID=79281779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3184128A Pending CA3184128A1 (en) 2020-06-23 2021-06-23 Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Country Status (10)

Country Link
US (1) US20240093318A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168593A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532444A (cg-RX-API-DMAC7.html)
KR (1) KR20230038486A (cg-RX-API-DMAC7.html)
CN (1) CN116096920A (cg-RX-API-DMAC7.html)
AU (1) AU2021297245A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026509A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184128A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000105A (cg-RX-API-DMAC7.html)
WO (1) WO2021262894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230158101A (ko) * 2021-03-18 2023-11-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 수술 위험도 점수를 생성하는 시스템 및 방법 및 그 용도
EP4303326A1 (fr) * 2022-07-06 2024-01-10 Biomérieux Determination du risque de deces d'un sujet infecte par un virus respiratoire par mesure du niveau d'expression du gene oas2
WO2024008955A1 (en) * 2022-07-08 2024-01-11 Age Labs As Method of screening for severe covid-19 susceptibility
CN117587124A (zh) * 2022-08-16 2024-02-23 武汉艾米森生命科技有限公司 诊断胰腺癌的检测试剂和试剂盒及应用
EP4484575A1 (de) * 2023-06-30 2025-01-01 Cerascreen GmbH Markersequenzen zur diagnose und therapiesteuerung von patienten mit testosteron-defizienz

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
WO2001041782A2 (en) 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
AU2001276371A1 (en) * 2000-06-30 2002-01-14 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
AU2004204751A1 (en) 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
ATE552843T1 (de) 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US7665238B2 (en) 2006-04-03 2010-02-23 S.C. Johnson & Son, Inc. Air freshener with holder
DK2148923T3 (da) 2007-05-18 2012-12-03 Medimmune Llc Konservering af biologisk aktive materialer med frysetørret skum
JP5985397B2 (ja) 2009-11-11 2016-09-06 アドバクシス インコーポレイテッド 組換えリステリア株およびそれを含む免疫原性組成物
WO2011082436A1 (en) * 2010-01-04 2011-07-07 Lineagen, Inc. Dna methylation biomarkers of lung function
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
AU2013370210B2 (en) 2012-12-27 2018-06-14 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CN106794235A (zh) 2014-07-18 2017-05-31 阿德瓦希斯公司 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
BR112019018272A2 (pt) * 2017-03-02 2020-07-28 Youhealth Oncotech, Limited marcadores metilação para diagnosticar hepatocelular carcinoma e câncer
CA3055895A1 (en) * 2017-03-10 2018-09-13 Self-Screen B.V. A methylation classifier for detection of hpv-induced invasive cancers, nonhpv- induced gynaecological and anogenital cancers and their high-grade precursor lesions

Also Published As

Publication number Publication date
EP4168593A4 (en) 2024-11-27
JP2023532444A (ja) 2023-07-28
KR20230038486A (ko) 2023-03-20
CN116096920A (zh) 2023-05-09
AU2021297245A1 (en) 2023-02-02
WO2021262894A1 (en) 2021-12-30
MX2023000105A (es) 2023-04-25
US20240093318A1 (en) 2024-03-21
EP4168593A1 (en) 2023-04-26
BR112022026509A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2024200059B2 (en) Methods and systems for analysis of organ transplantation
US20240093318A1 (en) Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes
US20240282449A1 (en) Methods and systems for machine learning analysis of inflammatory skin diseases
US20220399116A1 (en) Systems and methods for assessing a bacterial or viral status of a sample
AU2023226757A1 (en) Methods for diagnosis of bacterial and viral infections
US11257569B1 (en) Methods of assessing risk of developing a severe response to coronavirus infection
JP2025515307A (ja) 炎症を治療するためのトランスクリプトーム解析
Higham et al. Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease
Duffy Understanding immune variation for improved translational medicine
US20250391505A1 (en) Methods and Systems for Machine Learning Analysis of Lupus Nephritis
US20260117297A1 (en) Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy
US20220205042A1 (en) Molecular Signatures for Distinguishing Liver Transplant Rejections or Injuries
CN106119406B (zh) 多发性肉芽肿血管炎及微小动脉炎的基因分型诊断试剂盒及使用方法
EP3825418A2 (en) Molecular signatures for distinguishing liver transplant rejections or injuries
WO2024102200A9 (en) Methods and systems for evaluation of lupus based on ancestry-associated molecular pathways
EP4413164A1 (en) Screening method for rheumatoid arthritis
US20230340569A1 (en) Methods for detecting primary immunodeficiency
US11104951B2 (en) Molecular signatures for distinguishing liver transplant rejections or injuries
Deng et al. A novel Bayesian framework for harmonizing information across tissues and studies to increase cell type deconvolution accuracy
Cathomas et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19
Du Diagnosing and predicting clinical outcomes based on computational methods for immune microenvironment patterns: two examples
Liang et al. Study on the Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus Using Integrated Bioinformatics Method
Casanova Molecular Strategies to Distinguish Key Subphenotypes in Sarcoidosis
Li et al. A Unique Population of Lipid-Associated Macrophages in Cerebrospinal Fluid: Implications for NSCLC Leptomeningeal Metastases Development and Osimertinib Resistance

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250616

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250627

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250903

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250903

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250903

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260602